Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Rated “Moderate Buy” by Wall Street Analysts

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $37.25.

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday, October 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Citigroup raised their price target on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th.

View Our Latest Report on ZLAB

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB opened at $22.11 on Thursday. The stock’s 50-day moving average is $24.46 and its 200 day moving average is $21.35. Zai Lab has a 1 year low of $15.96 and a 1 year high of $29.02.

Zai Lab (NASDAQ:ZLAB – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. The company had revenue of $108.21 million during the quarter, compared to the consensus estimate of $107.90 million. As a group, analysts forecast that Zai Lab will post -2.19 EPS for the current fiscal year.

Insider Transactions at Zai Lab

In other Zai Lab news, Director Richard Gaynor acquired 1,228 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were acquired at an average cost of $27.19 per share, with a total value of $33,389.32. Following the transaction, the director owned 81,965 shares of the company’s stock, valued at $2,228,628.35. The trade was a 1.52% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

A number of large investors have recently added to or reduced their stakes in ZLAB. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zai Lab during the 3rd quarter valued at about $62,000. Nykredit A S purchased a new stake in Zai Lab during the second quarter valued at approximately $79,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Zai Lab during the 3rd quarter valued at $211,000. HighVista Strategies LLC purchased a new stake in shares of Zai Lab in the 3rd quarter worth $609,000. Finally, WealthPlan Investment Management LLC bought a new position in Zai Lab in the 3rd quarter worth $969,000. Institutional investors own 41.65% of the company’s stock.

About Zai Lab

(Get Free Report)

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.

Further Reading

Analyst Recommendations for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.